Efg Asset Management (Americas) Corp. Incyte Corp Transaction History

Efg Asset Management (Americas) Corp.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 09, 2023	SELL	$67.18 - $84.11 $12,159 - $15,223	-181 Reduced 5.61%	3,043 $244,000
Q3 2022 Nov 07, 2022	SELL	$66.18 - $82.86 $44,870 - $56,179	-678 Reduced 17.38%	3,224 $215,000
Q2 2022 Jul 13, 2022	SELL	$66.18 - $83.18 $78,489 - $98,651	-1,186 Reduced 23.31%	3,902 $296,000
Q1 2022 May 05, 2022	SELL	$66.02 - $79.71 $21,852 - $26,384	-331 Reduced 6.11%	5,088 $404,000
Q4 2021 Jan 24, 2022	BUY	$63.34 - $74.11 $29,833 - $34,905	471 Added 9.52%	5,419 $398,000
Q3 2021 Oct 22, 2021	BUY	$68.67 - $84.02 $58,506 - $71,585	852 Added 20.8%	4,948 $340,000
Q2 2021 Jul 23, 2021	BUY	$79.87 - $87.53 $327,147 - $358,522	4,096 New	4,096 $345,000
Q4 2017 Feb 07, 2018	SELL	$93.56 - $116.6 $403,430 - $502,779	-4,312 Closed	0 $0
Q3 2017 Nov 13, 2017	BUY	$109.15 - $138.27 $122,357 - $155,000	1,121 Added 35.13%	4,312 $503,000
Q2 2017 Aug 14, 2017	BUY	N/A	3,191	3,191 $402,000

643

186M

714K

557K

Ticker INCY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 222,431,008
Market Cap $16B
Description
Incyte Corporation, a biopharmaceutical company, focuses on the discovery, development, and commercialization of proprietary therapeutics in the United States and internationally. The company offers JAKAFI, a drug for the treatment of myelofibrosis and polycythemia vera; PEMAZYRE, a fibroblast growth factor receptor kinase inhibitor that act as ...

Get notified when there are updates to the investment portfolio of Efg Asset Management (Americas) Corp., based on Form 13F filings with the SEC.

Stay updated on Efg Asset Management (Americas) Corp. with notifications on news.